Nanomedical Theranostics in Cardiovascular Disease.

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.

• Authors: Jun Tang, Mark E Lobatto, Joanna C Read, Aneta J Mieszawska, Zahi A Fayad, Willem J M Mulder
• Journal: Current cardiovascular imaging reports (Curr Cardiovasc Imaging Rep) Vol. 5 Issue 1 Pg. 19-25 (Feb 2012) ISSN: 1941-9066 [Print] United States
• PMID: 22308199 (Publication Type: Journal Article)